FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors
forum
SUNPHARMA Share Price Discussion
Sun Pharmaceutical Industries Ltd.
NSE: SUNPHARMA | BSE: 524715 | ISIN: INE044A01036 | Sector: Pharmaceuticals and health care
SUNPHARMA Rating
- ★★
- ★★
- ★★
- ★★
- ★★
3.8/5 (25 Ratings)
SUNPHARMA Share Price *
478.05 +18.95 (4.13%)
* (quote may be delayed)
Find answers to all your questions on live SUNPHARMA message board: Is SUNPHARMA buy or sell? Should I buy SUNPHARMA shares? Why are SUNPHARMA shares falling? Should I invest in SUNPHARMA stock?
You can also check SUNPHARMA share price target recommended by brokerages.
SUNPHARMA Discussion Forum > Posts
Reputation: 3,001 • Today 4:03 AM
TV sees uptick in ad volumes; advertisers like Byju's and Netflix increase ad spends
New advertisers like Vivo, Cadbury, Kia Motors, Faasos , Bajaj, Sharp India, Hoichoi , Apple advertised on TV in week 20.
New advertisers like Vivo, Cadbury, Kia Motors, Faasos , Bajaj, Sharp India, Hoichoi , Apple advertised on TV in week 20.
Moneycontrol
Like
Reply
Reputation: 3,001 • Today 11:28 AM
Buy Sun Pharmaceutical Industries; target of Rs 540: ICICI Direct
ICICI Direct is bullish on Sun Pharmaceutical Industries has recommended buy rating on the stock with a target price of Rs 540 in its research report dated May 28, 2020.
ICICI Direct is bullish on Sun Pharmaceutical Industries has recommended buy rating on the stock with a target price of Rs 540 in its research report dated May 28, 2020.
Moneycontrol
Like
Reply
Reputation: 3,001 • Today 9:28 AM
Sun Pharma gains 5% on DGCI nod to initiate clinical trial of drug on COVID-19 patients
Nafamostat is approved in Japan for improvement of acute symptoms of pancreatitis and treatment of Disseminated Intravascular Coagulation (DIC).
Nafamostat is approved in Japan for improvement of acute symptoms of pancreatitis and treatment of Disseminated Intravascular Coagulation (DIC).
Moneycontrol
Like
Reply
Reputation: 10,502 • Today 3:00 AM
ICICIdirect.com target on SUNPHARMA
Date: 28-May-20
Broker: ICICIdirect.com
Price @ Call: 455.68
Target: 540
Recommendation: BUY
Like
Reply
Reputation: 3,001 • Yesterday 10:43 AM
Taking Stock | Market rises for second day in a row; investors richer by nearly Rs 2 lakh cr in a day
The overall market capitalisation of BSE-listed firms jumped to Rs 125.5 lakh crore on May 28 from Rs 123.6 lakh crore on May 27, making investors richer by Rs 1.9 lakh crore in a single day.
The overall market capitalisation of BSE-listed firms jumped to Rs 125.5 lakh crore on May 28 from Rs 123.6 lakh crore on May 27, making investors richer by Rs 1.9 lakh crore in a single day.
Moneycontrol
Like
Reply
Reputation: 3,001 • Yesterday 10:18 AM
Hold Sun Pharmaceutical Industries target of Rs 510: Sharekhan
Sharekhan recommended Hold rating on Sun Pharmaceutical Industries with a target price of Rs 510 in its research report dated May 27, 2020.
Sharekhan recommended Hold rating on Sun Pharmaceutical Industries with a target price of Rs 510 in its research report dated May 27, 2020.
Moneycontrol
Like
Reply
Reputation: 3,001 • Yesterday 10:13 AM
Buy Sun Pharma ; target of Rs 525: Motilal Oswal
Motilal Oswal is bullish on Sun Pharma has recommended buy rating on the stock with a target price of Rs 525 in its research report dated May 27, 2020.
Motilal Oswal is bullish on Sun Pharma has recommended buy rating on the stock with a target price of Rs 525 in its research report dated May 27, 2020.
Moneycontrol
Like
Reply
Reputation: 9,362 • Yesterday 9:27 AM
👉👉 SUN PHARMA IN PACT WITH SPARC TO TREAT SKIN DISORDERS. SUN PHARMA TO PAY 150 CR TO SPARC ADVANCED FOR DRUGS
Like
Reply
Reputation: 3,001 • Yesterday 8:48 AM
Buy Sun Pharmaceuticals; target of Rs 530: Dolat Capital
Dolat Capital is bullish on Sun Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 530 in its research report dated May 27, 2020.
Dolat Capital is bullish on Sun Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 530 in its research report dated May 27, 2020.
Moneycontrol
Like
Reply
Reputation: 3,001 • Yesterday 8:48 AM
Hold Sun Pharmaceutical Industries; target of Rs 467: Prabhudas Lilladher
Prabhudas Lilladher recommended Hold rating on Sun Pharmaceutical Industries with a target price of Rs 467 in its research report dated May 28, 2020.
Prabhudas Lilladher recommended Hold rating on Sun Pharmaceutical Industries with a target price of Rs 467 in its research report dated May 28, 2020.
Moneycontrol
Like
Reply
Reputation: 3,001 • Yesterday 6:03 AM
Buy Sun Pharmaceutical Industries; target of Rs 528: ICICI Securities
ICICI Securities is bullish on Sun Pharmaceutical Industries has recommended buy rating on the stock with a target price of Rs 528 in its research report dated May 27, 2020.
ICICI Securities is bullish on Sun Pharmaceutical Industries has recommended buy rating on the stock with a target price of Rs 528 in its research report dated May 27, 2020.
Moneycontrol
Like
Reply
Reputation: 3,001 • Yesterday 3:33 AM
Sun Pharma Standalone March 2020 Net Sales at Rs 2,836.08 crore, up 11.13% Y-o-Y
Moneycontrol
Like
Reply
Reputation: 3,001 • Yesterday 3:28 AM
What should investors do with Sun Pharma: buy, sell or hold post Q4?
CLSA has maintained buy rating but cut target to Rs 560 from Rs 590 per share.
CLSA has maintained buy rating but cut target to Rs 560 from Rs 590 per share.
Moneycontrol
Like
Reply
Reputation: 3,001 • Yesterday 3:08 AM
Sun Pharma Consolidated March 2020 Net Sales at Rs 8,184.94 crore, up 14.25% Y-o-Y
Moneycontrol
Like
Reply
Reputation: 10,502 • Yesterday 3:00 AM
Prabhudas Lilladher target on SUNPHARMA
Date: 28-May-20
Broker: Prabhudas Lilladher
Price @ Call: 455.33
Target: 467
Recommendation: HOLD
Like
Reply
Reputation: 3,001 • May 27 2:43 AM
Trade Setup for Thursday: Top 15 things to know before Opening Bell
The key support level for Nifty is placed at 9,101.47, followed by 8,887.98. If the index moves up, key resistance levels to watch out for are 9,431.22 and 9,547.48.
The key support level for Nifty is placed at 9,101.47, followed by 8,887.98. If the index moves up, key resistance levels to watch out for are 9,431.22 and 9,547.48.
Moneycontrol
Like
Reply
Reputation: 3,001 • May 27 8:58 AM
Sun Pharma Q4 profit falls 37% to Rs 399.8 crore on one-time loss; revenue ahead of estimates
The stock fell 19 percent during the quarter largely due to COVID-19-led market correction, but it gained 11 percent in the last one year, 6.3 percent year-to-date and 42 percent from March lows.
The stock fell 19 percent during the quarter largely due to COVID-19-led market correction, but it gained 11 percent in the last one year, 6.3 percent year-to-date and 42 percent from March lows.
Moneycontrol
Like
Reply
Reputation: 2,787 • May 27 5:15 AM
buy sunpharma in cash cmp 458 add more at 445 sl 438 tgt 500 result today #SUNPHARMA
Like
Reply
Reputation: -667 • May 27 3:28 AM
Like
Reply (6)
Latest replies
Rocket 🚀 🚀 🚀
3500+ profit now..
Boom boom
5000+ profit
Jackpot
8000 profit running
Soon to hit target
Booked full
8750 per lot
Reputation: 4,426 • May 27 2:57 AM
Like
Reply (1)
Latest replies
NEW HIGH 458++ 🚀
(1,250/- RISK PER LOT)😍
RISK 1: 2 TIMES PROFIT❤️
2,000/- PROFIT TILL NOW 👍
Reputation: 3,001 • May 27 1:18 AM
Sun Pharma Q4 profit, revenue expected to report healthy growth on low base
On the operating front, earnings before interest, tax, depreciation and amortisation (EBITDA) is expected to rise around 60 percent and margin may expand by more than 650 basis points YoY.
On the operating front, earnings before interest, tax, depreciation and amortisation (EBITDA) is expected to rise around 60 percent and margin may expand by more than 650 basis points YoY.
Moneycontrol
Like
Reply
Reputation: 3,599 • May 26 4:10 AM
SAGAANI in SUNPHARMA#SUNPHARMA buy sunpharma above 473 target 378-...
buy sunpharma above 473 target 478-483.5-489 stoploss 469.55
Like
Reply
Reputation: 3,599 • May 26 4:07 AM
buy sunpharma above 473 target 378-383.5-389 stoploss 369.55
Like
Reply
Reputation: 3,001 • May 23 5:43 AM
Hold Sun Pharmaceutical Industries; target of Rs 436: Prabhudas Lilladher
Prabhudas Lilladher recommended hold rating on Sun Pharmaceutical Industries with a target price of Rs 436 in its research report dated May 21, 2020.
Prabhudas Lilladher recommended hold rating on Sun Pharmaceutical Industries with a target price of Rs 436 in its research report dated May 21, 2020.
Moneycontrol
Like
Reply
Reputation: 132 • May 23 6:35 AM
Post by ChartArt in SUNPHARMA community on FrontPage
#ChartArt #EducationalPurposes #SUNPHARMA Bullish | Trendline breakout CMP 467
#ChartArt #EducationalPurposes #SUNPHARMA Bullish | Trendline breakout CMP 467
FrontPage
Like
Reply
- NewsBotToday 11:28 AMBuy Sun Pharmaceutical Industries; target of Rs 540: ICICI DirectMoneycontrolNewsBotToday 9:28 AMSun Pharma gains 5% on DGCI nod to initiate clinical trial of drug on COVID-19 patientsMoneycontrolNewsBotYesterday 10:18 AMHold Sun Pharmaceutical Industries target of Rs 510: SharekhanMoneycontrolNewsBotYesterday 10:13 AMBuy Sun Pharma ; target of Rs 525: Motilal OswalMoneycontrolNewsBotYesterday 8:48 AMBuy Sun Pharmaceuticals; target of Rs 530: Dolat CapitalMoneycontrolNewsBotYesterday 8:48 AMHold Sun Pharmaceutical Industries; target of Rs 467: Prabhudas LilladherMoneycontrolNewsBotYesterday 6:03 AMBuy Sun Pharmaceutical Industries; target of Rs 528: ICICI SecuritiesMoneycontrolNewsBotYesterday 3:33 AMSun Pharma Standalone March 2020 Net Sales at Rs 2,836.08 crore, up 11.13% Y-o-YMoneycontrolNewsBotYesterday 3:28 AMWhat should investors do with Sun Pharma: buy, sell or hold post Q4?MoneycontrolNewsBotYesterday 3:08 AMSun Pharma Consolidated March 2020 Net Sales at Rs 8,184.94 crore, up 14.25% Y-o-YMoneycontrol
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.